Franklin Resources’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Franklin Resources’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-24,226	Closed	-$44.8K	–	2797
2023 Q1	$44.8K	Hold	24,226	–	–	﹤0.01%	2199
2022 Q4	$26.9K	Sell	24,226 -3,621	-13%	-$5.15K	﹤0.01%	2257
2022 Q3	$65K	Buy	27,847 +249	+0.9%	+$882	﹤0.01%	2171
2022 Q2	$84K	Sell	27,598 -11,653	-30%	-$56.7K	﹤0.01%	2179
2022 Q1	$267K	Buy	39,251 +36	+0.1%	+$257	﹤0.01%	2058
2021 Q4	$327K	Sell	39,215 -106	-0.3%	-$873	﹤0.01%	2049
2021 Q3	$292K	Buy	+39,321	New	+$244K	﹤0.01%	2094

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Franklin Resources's JNCE Position: Q2 2023 in Review

Franklin Resources sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 24,226 shares — an estimated $44.8K sold.

Franklin Resources first reported a position in JNCE in Q3 2021 and held it in 7 quarters. The position peaked at $327K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Franklin Resources reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Franklin Resources sold 24,226 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $44.8K.
Franklin Resources first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Franklin Resources's Jounce Therapeutics, Inc. Common Stock position peaked at $327K in Q4 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Franklin Resources's 13F filing for Q2 2023, filed 11 Aug 2023.